Human Cancer Biology S 100 B Promotes GliomaGrowth throughChemoattraction of Myeloid-Derived Macrophages
Huaqing Wang,Leying Zhang,Ian Y. Zhang,Xuebo Chen,Anna Da Fonseca,Shihua Wu,Hui Ren,Sam Badie,Sam Sadeghi,Mao Ouyang,Charles D. Warden,Behnam Badie
2013-01-01
Abstract:Purpose: S100B is member of a multigenic family of Ca2þ-binding proteins, which is overexpressed by gliomas. Recently, we showed that low concentrations of S100B attenuatedmicroglia activation through the induction of Stat3. We hypothesized that overexpression of S100B in gliomas could promote tumor growth by modulating the activity of tumor-associated macrophages (TAM). Experimental Design:We stably transfected GL261 glioma cell lines with constructs that overexpressed (S100B) or underexpressed (S100B) S100B and compared their growth characteristics to intracranial wild-type (S100B) tumors. Results: Downregulation of S100B in gliomas had no impact on cell division in vitro but abrogated tumor growth in vivo. Interestingly, compared to S100B tumors, S100B and S100B intracranial gliomas exhibited higher infiltration of TAMs, stronger inflammatory cytokine expression, and increased vascularity. To identify the potential mechanisms involved, the expression of the S100B receptor, receptor for advanced glycation end products (RAGE), was evaluated in gliomas. Although S100B expression induced RAGE in vivo, RAGE ablation in mice did not significantly inhibit TAM infiltration into gliomas, suggesting that other pathwayswere involved in thisprocess. Toevaluateothermechanisms responsible forTAMchemoattraction,we then examined chemokine pathways and found that C-Cmotif ligand 2 (CCL2) was upregulated in S100B tumors. Furthermore, analysis of The Cancer Genome Atlas’s glioma data bank showed a positive correlation between S100B andCCL2 expression in humanproneural andneural glioma subtypes, supporting our finding. Conclusions: These observations suggest that S100B promotes glioma growth by TAM chemoattraction through upregulation of CCL2 and introduces the potential utility of S100B inhibitors for glioma therapy. Clin Cancer Res; 19(14); 3764–75. 2013 AACR. Introduction S100B is a member of the multigene family of Ca2þ -binding proteins of the EF-hand type and has been implicated in the regulation of cellular activities such as metabolism, motility, and proliferation (1, 2). In the nervous system, S100B is constitutively released by astrocytes into the extracellular space and at nanomolar concentrations, it can promote neurite outgrowth andprotect neurons against oxidative stress (3). S100B expression, however, can be augmented by various stimuli such as trauma and inflammation (4). Acting in an autocrine fashion, micromolar concentrations of S100B activate microglia and astrocytes through the induction of iNOS andNF-kB, and increase the expression of proinflammatory cytokines such as interleukin (IL)-1b, IL-6, and TNF-a (5–7). Through these functions, S100B has been implicated in the pathogenesis of neurodegenerative brain disorders such as Alzheimer’s disease (8). S100B is also overexpressed by most malignant gliomas. It is proposed to contribute to tumorigenesis by inhibiting the function of the tumor suppressor protein p53 (9, 10) and regulating cell proliferation and differentiation by stimulating the activity of the mitogenic kinases Ndr (11) and Akt (protein kinase B; ref. 12). Furthermore, S100B stimulates glioma proliferation at low concentrations (13) and modulates astrocyte function through an interaction with Src kinase (14). These reports suggest that S100B may contribute to astrocyte differentiation and could promote Authors' Affiliations: Department of Neurosurgery, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, Shandong Province; Department of General Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province; Research Center of Siyuan Natural PharmacyandBiotoxicology, College of Life Sciences, ZhejiangUniversity, Hangzhou; Department of Cardiology, Third Xiangya Hospital, Central South University, Changsha Hunan, P.R. China; Division of Neurosurgery; Bioinformatics Core, Department of Molecular Medicine; and Department of Cancer Immunotherapeutics & Tumor Immunology, Beckman Research Institute, City of Hope, Duarte, California; and Laboratório de Morfogênese Celular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Bolsista do CNPq, Rio de Janeiro, Brazil Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). H. Wang and L. Zhang contributed equally to this article. Corresponding Author: Behnam Badie, Division of Neurosurgery, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010. Phone: 626-471-7100; Fax: 626-471-7344; E-mail: bbadie@coh.org doi: 10.1158/1078-0432.CCR-12-3725 2013 American Association for Cancer Research. Clinical Cancer Research Clin Cancer Res; 19(14) July 15, 2013 3764 on May 6, 2017. © 2013 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from Published OnlineFirst May 29, 2013; DOI: 10.1158/1078-0432.CCR-12-3725